All analyses
AI analysis

Asiri Hospitals Ltd.: research report

Fairly valuedbullishNov 9, 2026

Evidence points bullish: June net margin was the best of seven comparable June quarters while the P/E is cheaper than 98% of its own history. The catch is a debt load covered only 2.87 times by operating profit.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • June net margin reached 14.3%, the best of seven comparable June quarters.
  • The 7.2 times P/E is cheaper than 98% of days since February 2012.
  • June net profit grew 11.1% year-on-year despite a 5.1% fall in operating profit, as below-the-line costs eased.

Against this. Debt was LKR 14.0 billion at March 2026 and operating profit covered the interest bill only 2.87 times.

Net margin
18.1%sector 13.0%
from 12.9% a year earlier, revenue +24.9%
Return on equity
11.7%sector 11.2%
full year to Mar 31, 2026
P/E
6.1sector 11.8
earnings Rs 5.07 per share, year to Sep 2026
P/B
1.31sector 1.36
book Rs 23.59 per share
Dividend yield
0.00%sector 0.00%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 9, 2026. Sector figures are the median of 6 listed companies in the same sector.

Overview

Asiri Health operates a nationwide private hospital, diagnostics and healthcare education network. The latest filed quarter combined continued revenue growth with higher net profit, but operating profit softened, making finance costs and cash generation important checks on the improvement.

Price performance

At LKR 31.60 on 9 November 2026, ASIR had risen 26.5% in one month against a 6.0% ASPI gain, but remained down 31.4% over six months while the ASPI fell 6.7%. The share is therefore recovering sharply over the short term after materially weaker medium-term performance than the index.

The price sits 34.8% of the way from its 52-week low to high. Recent volatility was 13.7% below its own one-year norm, while 20-day volume ran 29.7% above the prior 60-day level.

The three-year record contains three falls of 15% or more, the deepest 49%, which has not yet recovered. Median daily turnover was LKR 1.4 million; a LKR 1 million order is about 72% of what trades on a typical day, a large part of a day's trading.

Valuation

The share trades at 7.2 times earnings, or LKR 7.20 paid for each LKR 1 of trailing profit, and 1.41 times book value, or LKR 1.41 for each LKR 1 of net assets. Both sit below healthcare peer medians, although Asiri's 11.7% FY2026 ROE helps explain why it still trades above book value.

Against its own record, the P/E is cheaper than 98% of days since February 2012 and P/B is cheaper than 89% of days since February 2012. A buyer at this price is relying on the latest quarter for 25.7% of trailing EPS, but its 14.3% net margin was essentially unchanged from the year-ago quarter, leaving the P/E unchanged at 7.2 times on that margin comparison.

The market-wide valuation band is fairly valued, with the low earnings multiple offset by no current dividend yield. No dividend is on record in the last two years, so the valuation case rests on retained earnings rather than income distributions.

News and sentiment

Direct company coverage is thin: six material articles appeared over the last 90 days, split between two positive, three negative and one neutral. The main recent item, reported on 17 October 2026, concerned Asiri Central Hospital's response to social-media allegations of medical negligence and its stated cooperation with authorities; it did not disclose a financial effect.

There are no confirmed or pending corporate actions in the supplied record, and no dividend is on record in the last two years.

Financials

June-quarter revenue grew 9.1% year-on-year to LKR 9.5 billion and net profit rose 11.1% to LKR 1.4 billion, but operating profit fell 5.1%. Gross margin was 51.0% versus 50.9% a year earlier, operating margin was 20.3% versus 23.4%, and net margin was 14.3% versus 14.1%. In everyday terms, the group retained about 14 cents of profit from every LKR 1 of revenue, slightly more than a year earlier despite the weaker operating margin.

June has been the weakest quarter for gross margin on average over the six complete years on record, yet the 51.0% gross margin was the best of seven comparable June quarters. Net margin was also the best of seven June observations, while operating margin was middling at third of six. This makes the gross and net outcomes strong like-for-like results rather than merely a favourable quarter-of-year comparison.

The LKR 570 million gap between operating and net profit was lower than LKR 810 million a year earlier, helping net profit rise even as operating profit fell. Equity increased to LKR 27.9 billion from LKR 25.9 billion a year earlier, while the share count remained 1.14 billion, so the higher absolute profit was not diluted by a change in ordinary shares. Minority shareholders received 9.3% of FY2026 group profit, meaning group profit is not entirely attributable to the ordinary shares being valued.

Risks

The principal risk is leverage. At March 2026, debt was LKR 14.0 billion, equal to 58.9% of owners' equity, and operating profit covered interest expense 2.87 times. That leaves less room for a deterioration in hospital operating earnings or a higher financing burden.

Liquidity is also tight: the current ratio was 0.59 times, meaning the group had 59 cents of short-term assets, including receivables and supplies, for every LKR 1 of bills due within a year. Operating cash flow was only 0.65 times operating profit in FY2026, so not all accounting operating profit arrived as cash.

The current market backdrop includes higher inflation, fuel prices and a policy-rate increase as at 9 November 2026. These are market-wide conditions rather than company-specific events, but they matter more for a debt-funded operator with modest interest cover.

Outlook

As at 9 November 2026, the September 2026 interim filing was due, with the company's historical filing window running from 2 to 14 November. That release is the next evidence on whether the June result's higher net profit can coexist with softer operating profit and the current financing burden.

The available data cannot determine the outcome of the ongoing medical-negligence matter reported in October or any financial consequence. Healthcare-sector news as at 9 November focused on regulation and public healthcare policy rather than a disclosed Asiri-specific earnings driver.

About this report. Generated on Nov 9, 2026 from market data up to Nov 9, 2026, 6 material news articles over 90 days and financials to Jun 30, 2026, and scored 41 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports